2. Search Result
Search Result
Results for "

CK

" in MedChemExpress (MCE) Product Catalog:

270

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

10

Peptides

1

Inhibitory Antibodies

21

Natural
Products

38

Recombinant Proteins

7

Isotope-Labeled Compounds

116

Antibodies

1

Click Chemistry

7

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16926
    CK-666
    20+ Cited Publications

    		 Arp2/3 Complex HIV Infection Cancer
    CK-666 is a cell-permeable actin-related protein Arp2/3 complex inhibitor (IC50=12 μM). CK-666 binds to Arp2/3 complex, stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) conformation .
    CK-666
  • HY-139465
    Aficamten
    3 Publications Verification

    CK-274; CK-3773274

    		 Myosin Cardiovascular Disease
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM) .
    Aficamten
  • HY-50759
    Ispinesib
    5+ Cited Publications

    SB-715992; CK-0238273

    		 Kinesin Apoptosis Cancer
    Ispinesib is a specific inhibitor of kinesin spindle protein (KSP), with a Ki app of 1.7 nM.
    Ispinesib
  • HY-16927
    CK-869
    3 Publications Verification

    		 Arp2/3 Complex Cancer
    CK-869 is an Actin-Related Protein 2/3 (ARP2/3) complex inhibitor, with an IC50 of 7 μM.
    CK-869
  • HY-14233
    Omecamtiv mecarbil
    4 Publications Verification

    CK-1827452

    		 Myosin Cardiovascular Disease
    Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil
  • HY-139004
    SGC-CK2-1
    5 Publications Verification

    		 Casein Kinase Neurological Disease
    SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC50s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases .
    SGC-CK2-1
  • HY-109121
    Reldesemtiv
    2 Publications Verification

    CK-2127107

    		 Calcium Channel Cardiovascular Disease
    Reldesemtiv (CK-2127107) is a selective, orally active and next-generation fast skeletal muscle troponin activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC50 of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model .
    Reldesemtiv
  • HY-15535
    DMAT
    5+ Cited Publications

    CK2 Inhibitor; Casein kinase II Inhibitor

    		 Casein Kinase Cancer
    DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM.
    DMAT
  • HY-W011109
    CKI-7
    1 Publications Verification

    		 Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK) Cancer
    CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases .
    CKI-7
  • HY-15892
    CK-636
    4 Publications Verification

    CK-0944636

    		 Arp2/3 Complex Inflammation/Immunology Cancer
    CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC50 values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively. CK636 blocks cell migration.
    CK-636
  • HY-111820
    CK1-IN-1

    		Casein Kinase p38 MAPK Cardiovascular Disease
    CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis .
    CK1-IN-1
  • HY-159821
    Ulacamten

    CK-4021586; CK-586

    		 Myosin Cardiovascular Disease
    Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC50 of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .
    Ulacamten
  • HY-19815
    Olafertinib

    CK-101; RX518

    		 EGFR Cancer
    Olafertinib (CK-101) is an orally available, third generation and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Olafertinib selectively inhibits both EGFR-TKI-sensitizing and resistance mutations with minimal activity on wild-type EGFR. Olafertinib can be used in research for non-small cell lung cancer (NSCLC) with EGFR mutations and other advanced malignancies .
    Olafertinib
  • HY-132175
    CK2 inhibitor 2

    		Casein Kinase Cancer
    CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .
    CK2 inhibitor 2
  • HY-15964
    Tirasemtiv
    1 Publications Verification

    CK-2017357

    		 Biochemical Assay Reagents Neurological Disease
    Tirasemtiv is an activator of the fast skeletal muscle troponin complex. Tirasemtiv is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tirasemtiv
  • HY-133028
    CKI-7 free base
    1 Publications Verification

    		 Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK) Cancer
    CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases .
    CKI-7 free base
  • HY-158975
    VRK1/CK1-IN-1

    		Casein Kinase VRK Cancer
    VRK1/CK1-IN-1 (compound 36) is a dual VRK1 and CK1 family inhibitor, with a Ki of 37.9 nM against human VRK1, 8.3 nM against human CK1δ, and 7.8 nM against human CK1ε. VRK1/CK1-IN-1 exhibits extremely low activity against VRK2. VRK1/CK1-IN-1 can be used in studies related to p53-deficient tumors .
    VRK1/CK1-IN-1
  • HY-P2799A
    Creatine Kinase (CPK/CK), Bovine Heart
    1 Publications Verification

    CK, CPK, Creatine Phosphokinase

    		 Endogenous Metabolite Creatine Kinase Cardiovascular Disease
    Creatine Kinase (CPK/CK), Bovine Heart (CK) is a creatine kinase derived from bovine heart. Creatine Kinase (CPK/CK), Bovine Heart catalyzes the reversible phosphate transfer reaction between phosphocreatine and ADP, and is widely used in myocardial energy metabolism research and quality control of clinical biochemical tests .
    Creatine Kinase (CPK/CK), Bovine Heart
  • HY-147292
    Nelutroctiv

    CK-136

    		 Calcium Channel Cardiovascular Disease
    Nelutroctiv (CK-136) is an orally active and selective cardiac troponin activator. Nelutroctiv activates cardiac sarcomeres by enhancing the sensitivity of troponin to calcium ions and promoting the interaction between actin and myosin. Nelutroctiv enhances cardiac contractility. Nelutroctiv can be used in the researches for cardiovascular diseases with impaired cardiac contractile function .
    Nelutroctiv
  • HY-P99833
    Cosibelimab

    CK-301; TG-1501

    		 PD-1/PD-L1 Cancer
    Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
    Cosibelimab
  • HY-153866
    CK1-IN-2

    		Casein Kinase Cancer
    CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively .
    CK1-IN-2
  • HY-149006
    CK156

    		DAPK Inflammation/Immunology Cancer
    CK156, a chemical probe, is a highly selective death-associated protein kinase (DAPK) inhibitor with IC50s of 182 nM,34 μM, and 39 μM in the DRAK1 NanoBRET assay for DRAK1, CK2a1, and CK2a2, respectively. CK156 can be used for the research of autoimmune and inflammatory diseases .
    CK156
  • HY-135906
    CK2/ERK8-IN-1
    2 Publications Verification

    		 Casein Kinase ERK Pim DYRK Apoptosis Cancer
    CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy .
    CK2/ERK8-IN-1
  • HY-123312
    CK-548

    CK-0993548

    		 Arp2/3 Complex HIV Infection
    CK-548 (CK-0993548) is a Arp2/3 complex inhibitor with the IC50 of 11 μM. CK-548 inhibits HIV-1 nuclear migration and infection .
    CK-548
  • HY-162345
    CK-963

    		Calcium Channel Cardiovascular Disease
    CK-963 is an activator for cardiac troponin (cTnC) with Ki of 11.5 μM. CK-963 exhibits activity in enhancing cardiac contractility in Sprague-Dawley rats .
    CK-963
  • HY-117897
    CK-2-68
    1 Publications Verification

    		 Parasite Infection
    CK-2-68 is an inhibitor for complex III in protozoan mitochondrial respiratory chain, by targeting the alternative NADH dehydrogenase (NDH2) of the malarial parasite Plasmodium. CK-2-68 exhibits antimalaria efficacy, that inhibits Plasmodium falciparum infected erythrocytes with an IC50 of 40 nM .
    CK-2-68
  • HY-16516
    Vitamin CK3
    1 Publications Verification

    		 DNA/RNA Synthesis MMP Autophagy Cancer
    Vitamin CK3 is the combination of Vitamin C and vitamin K3 (100:1 ratio). Vitamin CK3 can decrease MMP activity. Vitamin CK3 can reactivate DNases and cause cell autophagy. Vitamin CK3 can be used for the research of cancer, such as lung cancer .
    Vitamin CK3
  • HY-145260
    BRD4/CK2-IN-1

    		Epigenetic Reader Domain Casein Kinase Apoptosis Autophagy Cancer
    BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC50s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)
    BRD4/CK2-IN-1
  • HY-103646
    CK7

    		NEKs CDK Others
    CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367 .
    CK7
  • HY-14233S
    Omecamtiv mecarbil-d8

    CK-1827452-d8

    		 Isotope-Labeled Compounds Myosin Cardiovascular Disease
    Omecamtiv mecarbil-d8 is the deuterium labeled Omecamtiv mecarbil. Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil-d8
  • HY-148318
    CK2α-IN-1

    		Casein Kinase Cancer
    CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies .
    CK2α-IN-1
  • HY-160532
    CK1α degrader-1
    1 Publications Verification

    		 Casein Kinase Cancer
    CK1α degrader-1 (Compound 82) is an orally active CK1α degrader with a DC50 of 0.105 μM. CK1α degrader-1 can be used for the research of cancer .
    CK1α degrader-1
  • HY-101436A
    Sematilide hydrochloride

    CK-1752 hydrochloride

    		 Potassium Channel Cardiovascular Disease
    Sematilide hydrochloride (CK-1752 hydrochloride) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K + current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent .
    Sematilide hydrochloride
  • HY-P2799D
    Creatine Kinase MB (rCK-MB), Recombinant Human
    1 Publications Verification

    CK-MB

    		 Biochemical Assay Reagents Others
    Creatine Kinase MB (rCK-MB), Recombinant Human (CK-MB) is a biological material or organic compound that can be used in life science research .
    Creatine Kinase MB (rCK-MB), Recombinant Human
  • HY-148328
    CK2-IN-4

    		Casein Kinase Infection Inflammation/Immunology Cancer
    CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC50=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis .
    CK2-IN-4
  • HY-158369
    CK2-IN-10

    		Casein Kinase Cancer
    CK2-IN-10 (31), an allosteric CK2 inhibitor, can be used in the research of cancer .
    CK2-IN-10
  • HY-P2799B
    Creatine Kinase (CK/CPK), Porcine Heart

    CPK, CK, Creatine Phosphokinase

    		 Biochemical Assay Reagents Others
    Creatine Kinase (CK/CPK), Porcine Heart (CPK, CK, Creatine Phosphokinase) is a biological material or organic compound that can be used in life science research .
    Creatine Kinase (CK/CPK), Porcine Heart
  • HY-178335
    SGC-CK1γ-1

    		LDLR Wnt CMV Infection
    SGC-CK1γ-1 is a potent and selective probe for the CK1γ subfamily. SGC-CK1γ-1 can inhibit LRP6 phosphorylation levels. SGC-CK1γ-1 can selectively inhibit the CK1γ kinases in living cells and inhibit both WNT signaling and human cytomegalovirus (CMV) replication. SGC-CK1γ-1 can be used for the research of infection .
    SGC-CK1γ-1
  • HY-P2799C
    Creatine Kinase BB (CK-BB) Isoenzyme, Porcine Brain

    CPK-1, CKBB isoenyzme, CK-BB

    		 Endogenous Metabolite Others
    Creatine Kinase BB (CK-BB) Isoenzyme, Porcine Brain (CPK-1, CKBB isoenyzme, CK-BB) is a biological material or organic compound that can be used in life science research .
    Creatine Kinase BB (CK-BB) Isoenzyme, Porcine Brain
  • HY-N0904R
    Ginsenoside C-K (Standard)

    Ginsenoside compound K(Standard); Ginsenoside K (Standard)

    		 Reference Standards COX NO Synthase Cytochrome P450 Inflammation/Immunology
    Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.
    Ginsenoside C-K (Standard)
  • HY-162043
    CKR-49-17

    		Amyloid-β Others
    CKR-49-17 is an activator of CK1γ2. CKR-49-17 decreases C99 and β-amyloid levels. CKR-49-17 can be used in the research of Alzheimer's disease (AD) .
    CKR-49-17
  • HY-19049
    CK-1649 chloride

    		Potassium Channel Cardiovascular Disease
    CK-1649 chloride is a class III antiarrhythmic agent. CK-1649 chloride can inhibit potassium channel activity .
    CK-1649 chloride
  • HY-115269
    CK-2289

    		Phosphodiesterase (PDE) Cardiovascular Disease
    CK-2289 is an inhibitor of type III cyclic 3'5'-adenosine monophosphate phosphodiesterase (PDE). CK-2289 can inhibit platelet aggregation and decreases mean arterial blood pressure. CK-2289 can be used for the research of cardiovascular disease, such as congestive heart failure .
    CK-2289
  • HY-174350
    CK2-IN-15

    		Casein Kinase SARS-CoV Infection
    CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC50 value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases .
    CK2-IN-15
  • HY-185104
    Ginsenoside C-K hexapropionate ester

    		LXR Cardiovascular Disease
    Ginsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1 by activating LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng saponins, by modification with propionic anhydride .
    Ginsenoside C-K hexapropionate ester
  • HY-170860
    CK1δ/CK1ε liagnd-1

    		Ligands for Target Protein for PROTAC Casein Kinase Cancer
    CK1δ/CK1ε liagnd-1 is the ligand for CK1δ/CK1ε that can be used for synthesis of CK1 PROTAC degrader AH078 (HY-170859) as the ligand for target protein .
    CK1δ/CK1ε liagnd-1
  • HY-117715
    CK-3197

    		Phosphodiesterase (PDE) Cardiovascular Disease
    CK-3197 is a weak inhibitor of Peak lll cyclic 3'5'-adenosine monophosphate phosphodiesterase (CAMP PDEl). CK-3197 has hemodynamic and myocardial energetic effects in vivo. CK-3197 is an imidazolone derivative used as a selective positive inotropic agent for congestive heart failure .
    CK-3197
  • HY-123195
    CK-119

    		Interleukin Related Cancer
    CK-119 is a potent interleukin-1 blocker. CK-119 inhibits the cell growth of fibroblast-like corneal and conjunctival cells, mainly by inhibiting DNA and RNA syntheses .
    CK-119
  • HY-151382
    CK2-IN-3

    		Casein Kinase Cancer
    CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM), with IC50 values of 1.51 μM (CK2α) and 7.64 μM (CK2α’). CK2-IN-3 can be used in the research of cancers .
    CK2-IN-3
  • HY-153788
    CK2-IN-7

    		Casein Kinase Cancer
    CK2-IN-7 (compound 2) is an inhibitor of casein kinase 2 (CK2). CK2-IN-7 shows synergistic effect with structurally distinct CK2 chemical probe: SGC-CK2-1, against cancer .
    CK2-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: